One of the objectives of HEcoPerMed is to identify existing financing and reimbursement models suitable to provide incentives for rapid development, translation and uptake of personalised medicine. To fulfil this objective, we performed a systematic literature review and identified 114 publications and reports that reported on financing and reimbursement models used for personalised medicine. Research and development of personalised medicine is usually financed through to public and private sources, including governments, the European Commission, Medical Research Councils, academia, manufacturers, venture capitalists and philanthropists, and health insurers. There is also an increasing trend in collaborations between the public and private sectors. Personalised medicine is reimbursed mainly through single fees, DRGs, and bundled payments. Risk-sharing outcome-based payments were applied primarily to gene, cell and targeted therapies (Luxturna, Kymriah,Strimvelis), and some companion diagnostics (OncotypeDX). The main barriers and disincentives to adoption of PM were the lack of demonstrable benefit in health technology assessment, and existing reimbursement billing and coding systems. Public-private financing agreements and risk-sharing outcome-based reimbursement could overcome current limitations in the development and uptake of personalised medicine, and pave the way to realise the full benefits of personalised medicine on individual health and healthcare system sustainability. A respective manuscript is currently submitted to a scientific journal and will be made available on our website as soon as it is published.